Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774407 · ClinicalTrials.gov registry record · Phase 2
Vaginal Estriol in Multiple Sclerosis
A Phase 2 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03774407 is a Phase 2 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 21 participants.
The verdict
NCT03774407, a Phase 2 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
Interventions
- DRUG vaginal estriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2020-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774407
The ClinicalTrials.gov registry entry for NCT03774407 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vaginal estriol is the first listed.
NCT03774407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03774407 about?
NCT03774407 is a clinical study titled "Vaginal Estriol in Multiple Sclerosis". Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
What is the current status of trial NCT03774407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2019-06-20. Estimated completion is 2020-11-29.
What interventions are being tested in trial NCT03774407?
The interventions under investigation include: vaginal estriol (DRUG).
Who is sponsoring clinical trial NCT03774407?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.